Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

35.76
+0.52001.48%
Post-market: 35.760.00000.00%16:00 EST
Volume:852.21K
Turnover:31.17M
Market Cap:4.05B
PE:-18.32
High:37.76
Open:35.29
Low:34.95
Close:35.24
52wk High:42.00
52wk Low:14.06
Shares:113.39M
Float Shares:64.72M
Volume Ratio:1.45
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9515
EPS(LYR):-2.5604
ROE:-39.94%
ROA:-20.70%
PB:5.57
PE(LYR):-13.97

Loading ...

NewAmsterdam Pharma Is Maintained at Buy by Needham

Dow Jones
·
3 hours ago

Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Moleculin Biotech (MBRX)

TIPRANKS
·
3 hours ago

Earnings Flash (NAMS) NewAmsterdam Pharma Posts FY 2025 Revenue $22.5M versus $45.6M a Year Ago

MT Newswires Live
·
Yesterday

NewAmsterdam (NAMS) posts FY 2025 net loss of USD 203.82 million (-15.66%)

Reuters
·
Yesterday

Press Release: NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Yesterday

NewAmsterdam Pharma gewährt neuen Mitarbeitern Aktienoptionen im Rahmen des 2024 Inducement Plans

Reuters
·
Feb 07

NewAmsterdam Pharma Executives to Join Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 04

NewAmsterdam Pharma Chief Accounting Officer Louise Kooij Reports Disposal of Common Shares

Reuters
·
Jan 28

NewAmsterdam Pharma CFO Mayur Ian Somaiya Reports Disposal of Common Shares

Reuters
·
Jan 23

RBC Raises Price Target on NewAmsterdam Pharma to $47 From $44, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 21

NewAmsterdam Pharma Company Nv : RBC Raises Target Price to $47 From $44

THOMSON REUTERS
·
Jan 21

Should NewAmsterdam’s Multi-Indication Obicetrapib Strategy Reshape How NAMS Investors View Pipeline Concentration?

Simply Wall St.
·
Jan 12

NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities

TIPRANKS
·
Jan 09

NewAmsterdam Pharma Enrolls First Patients in RUBENS Phase 3 Trial for Obicetrapib Combo in Metabolic Syndrome

Reuters
·
Jan 09

NewAmsterdam Pharma Outlines 2026 Strategic Priorities Including Anticipated EMA Approval Decision, Potential European Commercial Launch, and Ongoing Phase 3 Trials for Obicetrapib and Fixed-Dose Combination Therapies

Reuters
·
Jan 09

Press Release: NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

Dow Jones
·
Jan 09

NewAmsterdam Pharma Company Nv : Leerink Partners Raises Target Price to $55 From $45

THOMSON REUTERS
·
Jan 06

Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jan 06

NewAmsterdam Pharma Grants Stock Options to New Hire Under 2024 Inducement Plan

Reuters
·
Jan 06

Chief Accounting Officer Louise Kooij Sells Common Shares of NewAmsterdam Pharma Company NV

Reuters
·
Dec 30, 2025